En markant større andel af de patienter, der fik romiplostim, opnåede en varig trombocytrespons, end de patienter, der fik placebo i begge undersøgelser.
A significantly higher proportion of patients receiving romiplostim achieved a durable platelet response compared to patients receiving placebo in both studies.